New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2014
08:41 EDTGILD, ESRXAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.
News For GILD;ESRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 28, 2014
16:05 EDTESRXExpress Scripts reports Q3 adjusted EPS $1.29, consensus $1.29
Reports Q3 revenue $25.78B, consensus $24.93B. Reports Q3 adjusted claims 328.3M.
14:15 EDTGILDGilead October weekly 113 straddle priced for 5% move into Q3
Subscribe for More Information
13:20 EDTGILDGilead volatility increases into Q3 and outlook
Gilead October weekly call option implied volatility is at 69, November is at 43, December is at 40, and January is at 37; compared to its 26-week average of 33 according to Track Data, suggesting larger near term price movement into the expected release of Q3 results on October 28.
09:37 EDTGILDActive equity options trading
Subscribe for More Information
October 27, 2014
16:00 EDTGILDOptions Update; October 27, 2014
iPath S&P 500 VIX Short-Term Futures down 52c to 32.66. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR TWTR AMZN M NQ GILD C FB NFLX
08:27 EDTGILDGilead volatility elevated into Q3 and outlook
Gilead October weekly call option implied volatility is at 63, November is at 38, December and January is at 33; compared to its 26-week average of 33 according to Track Data, suggesting larger near term price movement into the expected release of Q3 results on October 28.
07:22 EDTGILDAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 24, 2014
16:02 EDTGILDOptions Update; October 24, 2014
Subscribe for More Information
11:55 EDTGILDStocks with call strike movement; YHOO GILD
Subscribe for More Information
October 23, 2014
08:35 EDTGILDGilead weekly volatility increases into Q3 and outlook
Gilead October weekly 31 call option implied volatility is at 43, December and January is at 33; compared to its 26-week average of 33 according to Track Data, suggesting larger near term price movement into the expected release of Q3 results on October 28.
October 22, 2014
09:38 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR AMZN C TWTR YHOO BAC GILD FB THRX DOW CAR
09:23 EDTESRXExpress Scripts getting more aggressive on pricing, says Cleveland Research
Subscribe for More Information
07:35 EDTGILDCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 21, 2014
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR AMZN C TWTR CVX VZ MCD GILD TXN
08:45 EDTGILDGilead Hep C drug barely used in California prisons due to cost, SFGate reports
Subscribe for More Information
October 20, 2014
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
October 17, 2014
16:01 EDTGILDOptions Update; October 17, 2014
iPath S&P 500 VIX Short-Term Futures down 1.75 to 38.58 Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
09:38 EDTGILDActive equity options trading on
Subscribe for More Information
October 16, 2014
13:31 EDTGILDGilead announces Harvoni Notice of Compliance from Health Canada
Gilead Sciences announced that Health Canada has issued a Notice of Compliance for Harvoni. Harvoni combines the NS5A inhibitor ledipasvir with the nucleotide analog polymerase inhibitor sofosbuvir, granted marketing authorization under the tradename Sovaldi in December 2013. The efficacy of Harvoni has been established in patients with chronic hepatitis C virus genotype 1 infection, with a treatment duration of eight, 12 or 24 weeks depending on prior treatment history, cirrhosis status and baseline viral load. Eight weeks of treatment with Harvoni can be considered for treatment-naive patients without cirrhosis who have baseline HCV viral load below 6M IU/mL. New Drug Submission applications are pending in Australia and New Zealand.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use